S&P 500   4,327.50 (+0.17%)
DOW   33,926.58 (-0.11%)
QQQ   358.51 (+0.17%)
AAPL   175.94 (+0.66%)
MSFT   316.60 (-0.13%)
META   298.53 (-0.18%)
GOOGL   130.63 (+0.29%)
AMZN   131.09 (+1.53%)
TSLA   244.44 (-0.18%)
NVDA   423.05 (+1.67%)
NIO   8.44 (-1.06%)
BABA   86.67 (-1.85%)
AMD   96.51 (+0.32%)
T   14.94 (-1.19%)
F   12.65 (+1.77%)
MU   68.85 (-0.04%)
CGC   0.94 (+11.82%)
GE   111.46 (+0.19%)
DIS   80.83 (-0.52%)
AMC   8.18 (+7.35%)
PFE   32.63 (-0.18%)
PYPL   58.51 (+1.09%)
NFLX   383.23 (+0.90%)
S&P 500   4,327.50 (+0.17%)
DOW   33,926.58 (-0.11%)
QQQ   358.51 (+0.17%)
AAPL   175.94 (+0.66%)
MSFT   316.60 (-0.13%)
META   298.53 (-0.18%)
GOOGL   130.63 (+0.29%)
AMZN   131.09 (+1.53%)
TSLA   244.44 (-0.18%)
NVDA   423.05 (+1.67%)
NIO   8.44 (-1.06%)
BABA   86.67 (-1.85%)
AMD   96.51 (+0.32%)
T   14.94 (-1.19%)
F   12.65 (+1.77%)
MU   68.85 (-0.04%)
CGC   0.94 (+11.82%)
GE   111.46 (+0.19%)
DIS   80.83 (-0.52%)
AMC   8.18 (+7.35%)
PFE   32.63 (-0.18%)
PYPL   58.51 (+1.09%)
NFLX   383.23 (+0.90%)
S&P 500   4,327.50 (+0.17%)
DOW   33,926.58 (-0.11%)
QQQ   358.51 (+0.17%)
AAPL   175.94 (+0.66%)
MSFT   316.60 (-0.13%)
META   298.53 (-0.18%)
GOOGL   130.63 (+0.29%)
AMZN   131.09 (+1.53%)
TSLA   244.44 (-0.18%)
NVDA   423.05 (+1.67%)
NIO   8.44 (-1.06%)
BABA   86.67 (-1.85%)
AMD   96.51 (+0.32%)
T   14.94 (-1.19%)
F   12.65 (+1.77%)
MU   68.85 (-0.04%)
CGC   0.94 (+11.82%)
GE   111.46 (+0.19%)
DIS   80.83 (-0.52%)
AMC   8.18 (+7.35%)
PFE   32.63 (-0.18%)
PYPL   58.51 (+1.09%)
NFLX   383.23 (+0.90%)
S&P 500   4,327.50 (+0.17%)
DOW   33,926.58 (-0.11%)
QQQ   358.51 (+0.17%)
AAPL   175.94 (+0.66%)
MSFT   316.60 (-0.13%)
META   298.53 (-0.18%)
GOOGL   130.63 (+0.29%)
AMZN   131.09 (+1.53%)
TSLA   244.44 (-0.18%)
NVDA   423.05 (+1.67%)
NIO   8.44 (-1.06%)
BABA   86.67 (-1.85%)
AMD   96.51 (+0.32%)
T   14.94 (-1.19%)
F   12.65 (+1.77%)
MU   68.85 (-0.04%)
CGC   0.94 (+11.82%)
GE   111.46 (+0.19%)
DIS   80.83 (-0.52%)
AMC   8.18 (+7.35%)
PFE   32.63 (-0.18%)
PYPL   58.51 (+1.09%)
NFLX   383.23 (+0.90%)
NASDAQ:TCON

TRACON Pharmaceuticals (TCON) Stock Forecast, Price & News

$0.21
-0.01 (-5.01%)
(As of 11:10 AM ET)
Compare
Today's Range
$0.20
▼
$0.21
50-Day Range
$0.21
▼
$0.37
52-Week Range
$0.18
▼
$2.19
Volume
35,278 shs
Average Volume
290,039 shs
Market Capitalization
$6.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

TRACON Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
2,759.9% Upside
$6.00 Price Target
Short Interest
Healthy
1.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.56) to ($1.72) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.66 out of 5 stars

See Top Rated MarketRank™ Stocks Here

TCON stock logo

About TRACON Pharmaceuticals (NASDAQ:TCON) Stock

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

TCON Price History

TCON Stock News Headlines

September 20, 2023 | americanbankingnews.com
TRACON Pharmaceuticals (NASDAQ:TCON) Receives New Coverage from Analysts at StockNews.com
September 18, 2023 | finance.yahoo.com
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
September 25, 2023 | Edge On The Street (Ad)
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
September 2, 2023 | finance.yahoo.com
7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot Pole
August 22, 2023 | msn.com
JonesTrading Downgrades TRACON Pharmaceuticals (TCON)
August 18, 2023 | finance.yahoo.com
TCON Aug 2023 2.500 call
August 16, 2023 | finanznachrichten.de
TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 15, 2023 | finance.yahoo.com
Q2 2023 TRACON Pharmaceuticals Inc Earnings Call
September 25, 2023 | Wall Street Fundamentals (Ad)
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
August 14, 2023 | finance.yahoo.com
TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 3, 2023 | finance.yahoo.com
TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023
July 11, 2023 | finance.yahoo.com
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma
June 20, 2023 | msn.com
What's Going On With TRACON Pharmaceuticals Shares Today
June 20, 2023 | finance.yahoo.com
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
June 16, 2023 | finance.yahoo.com
TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference
June 15, 2023 | finance.yahoo.com
TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma
May 30, 2023 | finance.yahoo.com
TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting
May 12, 2023 | msn.com
Maxim Group Maintains TRACON Pharmaceuticals (TCON) Buy Recommendation
May 12, 2023 | msn.com
Baird Maintains TRACON Pharmaceuticals (TCON) Outperform Recommendation
May 12, 2023 | msn.com
Recap: TRACON Pharma Q1 Earnings
May 11, 2023 | finance.yahoo.com
Q1 2023 TRACON Pharmaceuticals Inc Earnings Call
May 10, 2023 | finance.yahoo.com
TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023 | finance.yahoo.com
TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 3, 2023 | finance.yahoo.com
TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023
May 1, 2023 | msn.com
Short Volatility Alert: Tracon Pharmaceuticals
April 25, 2023 | msn.com
Tracon Pharmaceuticals Plunges after Unfavorable Arbitration Ruling
April 25, 2023 | msn.com
Tracon stock slumps ~15% after I-Mab gets favorable ruling in arbitration
See More Headlines
Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TCON Company Calendar

Last Earnings
8/14/2023
Today
9/25/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCON
CUSIP
N/A
CIK
1394319
Web
www.traconpharma.com
Phone
(858) 550-0780
Fax
858-550-0786
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+2,658.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.17)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-29,140,000.00
Net Margins
N/A
Pretax Margin
-313.58%
Return on Equity
N/A
Return on Assets
-159.92%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.41
Quick Ratio
0.41

Sales & Book Value

Annual Sales
$350,000.00
Price / Sales
19.08
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.33) per share
Price / Book
-0.66

Miscellaneous

Outstanding Shares
30,700,000
Free Float
29,082,000
Market Cap
$6.68 million
Optionable
Not Optionable
Beta
1.24
A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Charles P. Theuer M.D. (Age 59)
    Ph.D., CEO, Pres & Director
    Comp: $803.7k
  • Mr. Scott B. Brown CPA (Age 42)
    M.S., Chief Financial Officer
    Comp: $451.64k
  • Ms. Bonne Adams M.B.A. (Age 46)
    Chief Operating Officer
  • Mr. Shahe Garabedian
    Sr. VP & Head of Quality Assurance
  • Dr. James L. Freddo (Age 68)
    Chief Medical Officer
  • Mr. Ya Huang
    Exec. Director of Statistical Programming
  • Dr. Brenda Marczi Pharm.D.
    Pharmd Mba, Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TCON Stock - Frequently Asked Questions

Should I buy or sell TRACON Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TCON shares.
View TCON analyst ratings or view top-rated stocks.

What is TRACON Pharmaceuticals' stock price forecast for 2023?

3 Wall Street analysts have issued twelve-month price objectives for TRACON Pharmaceuticals' shares. Their TCON share price forecasts range from $3.00 to $12.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 2,658.6% from the stock's current price.
View analysts price targets for TCON or view top-rated stocks among Wall Street analysts.

How have TCON shares performed in 2023?

TRACON Pharmaceuticals' stock was trading at $1.49 at the beginning of 2023. Since then, TCON shares have decreased by 85.4% and is now trading at $0.2175.
View the best growth stocks for 2023 here.

Are investors shorting TRACON Pharmaceuticals?

TRACON Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totaling 404,700 shares, an increase of 70.1% from the August 15th total of 237,900 shares. Based on an average daily volume of 473,100 shares, the short-interest ratio is presently 0.9 days.
View TRACON Pharmaceuticals' Short Interest.

When is TRACON Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our TCON earnings forecast.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) released its quarterly earnings data on Monday, August, 14th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.30. The biopharmaceutical company had revenue of $9 million for the quarter.

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.95%), Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier and Scott B Brown.
View institutional ownership trends.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $0.22.

How much money does TRACON Pharmaceuticals make?

TRACON Pharmaceuticals (NASDAQ:TCON) has a market capitalization of $6.68 million and generates $350,000.00 in revenue each year. The biopharmaceutical company earns $-29,140,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The official website for the company is www.traconpharma.com. The biopharmaceutical company can be reached via phone at (858) 550-0780, via email at ir@traconpharma.com, or via fax at 858-550-0786.

This page (NASDAQ:TCON) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -